Evidence map›Paper›PMID 40534840›Full record

ArticleFrontiers in genetics2025

Jonathan N Katsukunya, Revina Naicker, Nyarai D Soko, Dirk Blom, Phumla Sinxadi, Emile R Chimusa, Brian Rayner, Erika Jones, Collet Dandara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jonathan N KatsukunyaDivision of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IIDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Revina NaickerDivision of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IIDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Nyarai D SokoDivision of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IIDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Dirk BlomSAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Phumla SinxadiSAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Emile R ChimusaDepartment of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, United Kingdom.
Brian RaynerSAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Erika JonesSAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Collet DandaraDivision of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IIDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Genetic variation in genes coding for enzymes metabolising antihypertensive drugs, may affect the efficacy of angiotensin converting enzyme (ACE) inhibitors such as enalapril, potentially leading to resistant hypertension (RHTN). We set out to evaluate the contribution of genetic variation in Methods: Using a retrospective age, sex and ethnicity matched case-control study design, 379 participants with hypertension belonging to the African and MA ethnic groups were recruited. Cases were participants with RHTN (i.e., blood pressure (BP) ≥140/90 mmHg on ≥3 antihypertensive drugs or BP < 140/90 mmHg on >3 antihypertensive drugs, including a diuretic). Cases were matched to controls with similar characteristics (age (±5 years), sex and ethnicity) in a 1:1 ratio. Controls were participants with hypertension that was under control (BP < 140/90 mmHg on ≤3 antihypertensive drugs). Five polymorphisms in Results and discussion: Conclusion:

Indexed as

ACE inhibitorsAfricansCES1enalaprilhypertensionNOS3pharmacogenomics

Identifiers

PMID40534840
PMCPMC12174097

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.